Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Royalty Pharma Plc Cl A (NQ: RPRX )

27.09 +0.09 (+0.33%)
Official Closing Price Updated: 4:15 PM EDT, Jun 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Royalty Pharma Plc Cl A

< Previous 1 2 Next >
Royalty Pharma Reports First Quarter 2023 Results
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma To Present At The BofA Securities 2023 Health Care Conference
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Declares Second Quarter 2023 Dividend
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma to Announce First Quarter 2023 Financial Results on May 9, 2023
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Announces $1.0 Billion Share Repurchase Program
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million
From Royalty Pharma plc
Via GlobeNewswire
PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million
From PureTech Health plc
Via Business Wire
Royalty Pharma Raises Full Year 2023 Guidance
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Appoints Ashwin Pai as Executive Vice President, Investments
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Reports Q4 and Full Year 2022 Results
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma to Present at Upcoming Investor Conferences
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma To Announce Fourth Quarter And Full Year 2022 Financial Results On February 15, 2023
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Highlights Accomplishments and Provides Business Update at 41st Annual J.P. Morgan Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Announces Dividend Increase
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 9
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Announces Expansion of Senior Leadership Team
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future Milestones
From Royalty Pharma plc
Via GlobeNewswire
Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Royalty Pharma Reports Third Quarter 2022 Results
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma to Announce Third Quarter 2022 Financial Results on November 8, 2022
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Declares Fourth Quarter 2022 Dividend
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Announces Expansion of Leadership Team
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Announces R&D Funding Collaboration With Merck
Novel collaboration structure supports pipeline innovation 
From Royalty Pharma plc
Via GlobeNewswire
Dicerna Sells OXLUMO™ (lumasiran) Royalty Interest to Royalty Pharma for Up to $240 Million
From Dicerna Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.